Results 201 to 210 of about 4,253,992 (294)

Programmable ZBTB7A RNA N⁶-methyladenosine site-specific demethylation suppresses colorectal cancer liver metastasis. [PDF]

Mol Cancer
Chen X, Zhao S, Liu B, Fan Y, Qiu H, Ren L, Zhang X, Yan S, An Y, Li S, An J, Wang J, Hu H.   +12 more
europepmc   +1 more source

From pathogen to “living drug factory” innovative strategies and clinical translation of bacteria as programmable intelligent vectors for cancer therapy

BMEMat, EarlyView.
Engineered bacteria serve as smart, living therapeutics that target tumors, deliver drugs, and remodel immunosuppressive microenvironments. This review highlights their potential to potentiate immunotherapy, radiotherapy, and chemotherapy, offering a promising paradigm for precise and synergistic cancer treatment. Abstract The dynamic interplay between
Haonan Shen, Weichen Zhang, Gaoli Niu, Li Wang, Ruiyan Li, Yueyue Fan, Feixue Lu, Lingling Xu, Xiaoyuan Ji, Yong Kang   +9 more
wiley   +1 more source

Key molecular mechanisms and regulatory networks in colorectal cancer liver metastasis. [PDF]

Biol Proced Online
Zhang Z, Ni Y, Wang J, Tian J, Liu L, Hao S.   +5 more
europepmc   +1 more source

Innovation of plant‐derived extracellular vesicles and interdisciplinary research: From discovery to biomedical applications

BMEMat, EarlyView.
Plant‐derived extracellular vesicles offer numerous advantages and are regarded as highly promising candidates in the field of biomedicine. Abstract Extracellular vesicles (EVs) are double‐membrane vesicular structures that can be secreted by nearly all living cells.
Zilin Li, Yi Wei, Ben Hu, Yafang Song, Xiaojia Chen, Nik Ahmad Nizam Nik Malek, Tongkai Chen   +6 more
wiley   +1 more source

Intratumoral <i>Bacillus</i> regulating colorectal cancer liver metastasis: links to lipid metabolism and APOE⁺ macrophages. [PDF]

Front Immunol
Chu J, Huang H, Hu Y, Wang Q, Yuan T, Huang S, Lin J, He C, Li H, Shen H, Li J.   +10 more
europepmc   +1 more source

Nanoagonist‐mediated spatiotemporal reprogramming of macrophage phenotypes to potentiate tumor immunotherapy

BMEMat, EarlyView.
This review systematically summarizes the major molecular mechanisms governing TAM polarization and their coordinated interactions. It further highlights recent advances in nanoagonist‐based strategies that intervene in these pathways to reprogram TAMs, critically discussing their therapeutic potential, current limitations, and translational prospects.
Siqi Fang, Fengfeng Xiao, Ruie Chen, Cuixia Lu, Yi Ju, Mingqing Yuan, Yunlu Dai, Liewei Wen   +7 more
wiley   +1 more source

MicroRNA-345-3p expression inhibits colorectal cancer liver metastasis by targeting KHDRBS1 and TGF-β signaling pathway. [PDF]

Hereditas
Fan S, Zhao J, Liu S, Xu B, Cheng X.
europepmc   +1 more source

Turning Bonding Into Function: The Emerging Role of the Bioactive Selenium─Metal Motif in Toxicology and Medicinal Chemistry

Chemistry – A European Journal, EarlyView.
Balancing Act: Se─M bond serving as the fulcrum of the balance scale to compare the different weight of toxicity and therapeutic effects in biological environment. ABSTRACT The synthesis and characterization of organo‐selenium compounds have attracted considerable interest for decades, driven by the search for efficient catalysts and bioinspired ...
Matteo Filippi, Alessandro Rubbi, Pablo A. Nogara, Giovanni Ribaudo, Vito Lippolis, João B. T. Rocha, Laura Orian   +6 more
wiley   +1 more source

Single-cell and spatial transcriptomic landscapes reveal PIGT as a pivotal regulator of immunometabolic remodeling in colorectal cancer liver metastasis. [PDF]

Funct Integr Genomics
Yan M, Li Y, Liu Y, Peng L, Zhou H.
europepmc   +1 more source

Population Pharmacokinetics and Exposure‐Response Analyses to Support Cofetuzumab Pelidotin (ABBV‐647) Dose Optimization in Non‐Small Cell Lung Cancer Patients

Clinical Pharmacology &Therapeutics, EarlyView.
Cofetuzumab pelidotin (Cofe‐P) is an anti‐protein tyrosine kinase 7 (PTK7) antibody‐drug conjugate (ADC) being investigated for the treatment of adults with PTK7‐expressing, recurrent non‐small cell lung cancer (NSCLC). The first‐in‐human (FIH) trial demonstrated tolerability of dosages ≤ 2.8 mg/kg once every 3 weeks (Q3W) and ≤ 3.2 mg/kg Q2W ...
Carla Biesdorf, Melanie Rinas, Benjamin Engelhardt, Rabih Saab, Cen Guo, Cristiano Ferlini, Kevin J. Freise, Rajeev M. Menon, Akshanth R. Polepally   +8 more
wiley   +1 more source